Management of panic disorder

References

• Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S. Panic attacks in the community. Social morbidity and health care utilization. JAMA 265, 742–746 (1991).
   PubMed Web of Science ®Google Scholar
• Robins LN, Regier DA. (Eds). Psychiatric Disorders in America: the Epidemiologic Catchment Area Study. Free Press, NY, USA (1991).
   Google Scholar
• Weissman MM, Bland MB, Canino GJ et al. The cross-national epidemiology of panic disorder. Arch. Gen. Psych. 54, 305–309 (1997).
   PubMed Web of Science ®Google Scholar
• DeLoof C, Zandbergen H, Lousberg T et al. The role of life events in the onset of panic disorder. Behav. Res. Ther. 27, 461–463 (1989).
   PubMedGoogle Scholar
• Rapee RM, Mattick RP, Murrell E. Impact of life events on subjects with panic disorder and on comparison subjects. Am. J. Psychiatry 147, 640–644 (1990).
   PubMed Web of Science ®Google Scholar
• Hirschfield RMA. Panic disorder: diagnosis, epidemiology and clinical course. J. Clin. Psychiatry 57, 3–8 (1996).
   Google Scholar
• Page AC, Andrews G. Do specific anxiety disorders show specific drug problems? Aust. NZ J. Psychiatry 30, 410–414 (1996).
   PubMed Web of Science ®Google Scholar
• Gorman JM, Caplan JD. Comorbidity of depression and panic disorder. J. Clin. Psychiatry 57, 34–41 (1996).
   PubMed Web of Science ®Google Scholar
• Tyrer P, Seivewright H, Simmonds S et al. Prospective studies of cothymia (mixed anxiety-depression): how do they inform clinical practice? Eur. Arch. Psychiatry Clin. Neurosci. 251, 1153–1156 (2001).
   Google Scholar
• Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 3, 171–199 (2002).
   PubMedGoogle Scholar
• Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta analysis. Int. Clin. Psychopharmacol.10, 45–49 (1995).
   PubMed Web of Science ®Google Scholar
• Bakker A, van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta analysis. Acta Psychiat. Scand. 106, 163–167 (2002).
   PubMed Web of Science ®Google Scholar
• Otto M, Tuby K, Gould R et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am. J. Psychiatry 158, 1989–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Lepola UM, Wade AG, Leinonen EV et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J. Clin. Psychiatry 59, 528–534 (1998).
   PubMed Web of Science ®Google Scholar
• Wade AG, Lepola U, Koponen HJ et al. The effect of citalopram in panic disorder. Br. J. Psychiatry 170, 549–553 (1997).
   PubMed Web of Science ®Google Scholar
• Rapaport M, Wolkow R, Rubin A et al. Sertraline treatment of panic disorder: results of a long term study. Acta Psych. Scand. 104, 289–298 (2001).
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psych. Scand. 95, 153–160 (1997).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Behnke K, Lenoir S et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute double-blind noninferiority comparison. J. Clin. Psychiatry 65, 405–413 (2004).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Worthington JJ, Otto MW et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharm. Bull. 32, 667–670 (1996).
   PubMed Web of Science ®Google Scholar
• Bertani A, Perna G, Migliarese G et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized single-blind study. Pharmacopsychiatry 37, 206–210 (2004).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch. Gen. Psych. 37, 51–59 (1980).
   PubMed Web of Science ®Google Scholar
• Loerch B, Graf-Morgenstern M, Hautzinger et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br. J. Psychiatry 174, 205–212 (1999).
   PubMed Web of Science ®Google Scholar
• Uhlenhuth EH, Warner TD, Matuzas W. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J. Clin. Psychopharmacol.22, 275–284 (2002).
   PubMedGoogle Scholar
• Curtis GC, Massana J, Udina C et al. Maintenance drug therapy of panic disorder. J. Psychiatr. Res.27, 127–142 (1993).
   PubMed Web of Science ®Google Scholar
• Rickels K. Alprazolam extended-release in panic disorder. Expert Opin. Pharmacother. 5, 1599–1611 (2004).
   PubMed Web of Science ®Google Scholar
• Bouvard M, Mollard E, Guenn J et al. Study and course of the psychological profile in 77 patients experiencing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychother. Psychosom. 66, 27–32 (1997).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Ruther E. Treatment-resistant panic disorder. CNS Spectr. 9, 725–739 (2004).
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Caplan JD, Gorman JM. Management of treatment-refractory panic disorder. Pharmacol. Bull. 35, 97–110 (2001).
   Google Scholar
• Pollack MH, Simon NM, Worthington JJ et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacol. 17, 276–282 (2003).
   PubMed Web of Science ®Google Scholar
• Doyle A, Pollack MH. Long-term management of panic disorder. J. Clin. Psych. 65(Suppl. 5), 24–28 (2004).
   Google Scholar
• Heuzenroeder L, Donnelly M, Haby E et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. NZ J. Psych. 38, 602–612 (2004).
   PubMed Web of Science ®Google Scholar
• Williams SL, Falbo J. Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Behav. Res. Ther.34, 253–264 (1996).
   PubMed Web of Science ®Google Scholar
• Barlow DH, Gorman JM, Shear MK et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomised controlled trial. JAMA283, 2529–2536 (2000).
   PubMed Web of Science ®Google Scholar
• Beck AT, Sokol L, Clark DA et al. A crossover study of focused cognitive therapy for panic disorder. Am. J. Psychiatry 149, 778–783 (1992).
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Michelson L. Agoraphobia, behavioral and pharmacological treatment (n = 49). Pharmacol. Bull. 19, 116–118 (1983).
   Google Scholar
• Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch. Gen. Psych. 53, 689–694 (1996).
   PubMed Web of Science ®Google Scholar
• Bruce SE, Vasile RG, Keller, MB et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am. J. Psychiatry 160, 1432–1438 (2003).
   PubMed Web of Science ®Google Scholar